The Patent Finder

D&D Pharmatech Inc.

8 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3
Ending by 2030
Nov 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Mar 10, 2027
    The maintenance fee for Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient (US 10,406,230) comes due Mar 10, 2027. Unpaid by Sep 10, 2027, it lapses early.
  • 1 fee due Oct 26, 2027
    The maintenance fee for N-Terminal Modified Peg-Trail (US 9,321,825) comes due Oct 26, 2027. Unpaid by Apr 26, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

PatentTitleStatus Expires Confidence
US 8,420,598Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 8,466,103Exendin polypeptide linked to biotin, method for the preparation thereof and pharmaceutical composition comprising the same
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,321,825N-Terminal Modified Peg-Trail
In force
 · High confidence
In forceHigh confidence
US 10,406,230Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,901,620Trail receptor agonists for treatment of fibrotic disease
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,299,528Long acting TRAIL receptor agonists for treatment of autoimmune diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,046,059Methods of Administering an N-Terminal Modified Peg-Trail
In force
 · High confidence
In forceHigh confidence
US 12,338,270Pharmaceutical Composition Comprising Polypeptide
In force
 · High confidence
In forceHigh confidence

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 1 no status recorded

Showing 1 to 6 of 6, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.

ApplicationTitleFiledStatus
19/194,851Pharmaceutical Composition Comprising PolypeptideApr 30, 2025Pending
18/869,214Peptide Compositions and Methods of Use ThereofMay 26, 2023Pending
18/690,140Pharmaceutical Composition Comprising Large Physiologically Active Substance and ExcipientSep 7, 2022Pending
18/039,184Oral Formulation of Biologically Active Material Conjugate Having Biotin Moiety, Fatty Acid Moiety, or Combination Thereof Coupled TheretoNov 29, 2021Pending
17/778,759Nov 20, 2020No status recorded
17/615,504Physiologically Active Substance Bound to Biotin Moiety, and Composition for Oral Administration Including SameMay 29, 2020Pending
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited